Genitourinary Cancer: Clinical Trials
Dr. Tagawa leads clinical trials in prostate, renal (kidney), and urothelial (bladder) cancers. The genitourinary section of the solid tumor program includes local, regional, national, and international trials. Weill-Cornell is a main member institution of Cancer and Leukemia Group B (CALGB) and Dr. Tagawa actively participates in the genitourinary section of this national cancer research group. In addition, clinical trials are available through a contract with the National Cancer Institute (NCI) as part of the New York Cancer Consortium.Dr. Tagawa has a specific interest in monoclonal antibody directed therapy, in particular using antibodies against prostate specific membrane antigen (PSMA) and holds grants in this area. He leads clinical trials using radioimmunotherapy (small radioactive particles linked to the antibody) to fight metastatic prostate cancer, to prevent or delay metastatic disease in men with a rising PSA, and targeting tumor vasculature in advanced solid tumors.